Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 6Sezary Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Leukemia 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Panobinostat × Clear all
NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡